New research indicates that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who stop conventional diet and exercise plans.
Findings released in a prominent medical journal shows that while obese individuals often shed a large proportion of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"People purchasing such treatments must be aware of the potential of rapid rebound weight gain when the treatment is stopped," stated expert Dr. Susan Jebb.
That rate of regain suggests a reversion to starting weight within about a year and a half.
Weighing Therapies
The analysis, which examined 37 of studies involving over 9,000 of patients, compared the results of these new drugs with older methods.
The team point out that individuals who shed pounds through lifestyle changes alone typically see a less rapid weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Doctors propose the mechanism of the jabs explains the heightened regain.
The injections mimic a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication results in appetite is uncontrolled, making binge eating a significant risk."
An Ongoing Disease?
Medical guidelines suggest the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts contend that, considering the significant potential of weight regain, the therapy is often long-term.
This opinion is supported by drug manufacturers, who say that the findings "highlight the long-term nature of obesity," akin to managing conditions like high blood pressure.
User Accounts
Users who have come off the jabs report a powerful resurgence of appetite.
"It felt as if a switch that goes on and you're instantly ravenous," said a patient.
This challenge is compounded if patients have not adopted lasting dietary or behavioural changes during treatment.
Significant Interest
Figures suggest that millions of adults in the UK have used these injections in the past year, with interest remaining high.
- Use is higher among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic solution and lasting health benefits relies on ongoing behavioural changes.
